Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.21
(-0.48%)
HKD 0.21
(-0.48%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 301.53 Million HKD | -74.73% |
| 2022 | 1.19 Billion HKD | -4.97% |
| 2021 | 1.25 Billion HKD | 1.24% |
| 2020 | 1.24 Billion HKD | -14.96% |
| 2019 | 1.45 Billion HKD | 114.14% |
| 2018 | 681.01 Million HKD | 34.54% |
| 2017 | 506.16 Million HKD | 16.2% |
| 2016 | 435.61 Million HKD | -18.28% |
| 2015 | 533.07 Million HKD | 78.2% |
| 2014 | 299.14 Million HKD | 203.07% |
| 2013 | 98.7 Million HKD | 205.72% |
| 2012 | -93.36 Million HKD | -12837.52% |
| 2011 | 733 Thousand HKD | 102.46% |
| 2010 | -29.73 Million HKD | 0.23% |
| 2009 | -29.8 Million HKD | -195.24% |
| 2008 | 31.29 Million HKD | -76.29% |
| 2007 | 131.98 Million HKD | 174.42% |
| 2006 | -177.35 Million HKD | -830.83% |
| 2005 | 24.26 Million HKD | -79.12% |
| 2004 | 116.23 Million HKD | 168.19% |
| 2003 | 43.34 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 988.32 Million HKD | 0.0% |
| 2023 FY | 301.53 Million HKD | -74.73% |
| 2023 Q4 | 301.53 Million HKD | 0.0% |
| 2022 Q2 | 1.14 Billion HKD | 0.0% |
| 2022 FY | 1.19 Billion HKD | -4.97% |
| 2022 Q4 | 1.19 Billion HKD | 0.0% |
| 2021 Q4 | 1.25 Billion HKD | 0.0% |
| 2021 Q2 | 1.26 Billion HKD | 0.0% |
| 2021 FY | 1.25 Billion HKD | 1.24% |
| 2020 Q4 | 1.24 Billion HKD | 0.0% |
| 2020 FY | 1.24 Billion HKD | -14.96% |
| 2020 Q2 | 1.25 Billion HKD | 0.0% |
| 2019 FY | 1.45 Billion HKD | 114.14% |
| 2019 Q2 | 430.7 Million HKD | 0.0% |
| 2019 Q4 | 1.83 Billion HKD | 0.0% |
| 2018 Q4 | 681.01 Million HKD | 0.0% |
| 2018 Q2 | 699.01 Million HKD | 0.0% |
| 2018 FY | 681.01 Million HKD | 34.54% |
| 2017 FY | 506.16 Million HKD | 16.2% |
| 2017 Q2 | 503.46 Million HKD | 0.0% |
| 2017 Q4 | 506.16 Million HKD | 0.0% |
| 2016 Q4 | 435.61 Million HKD | 0.0% |
| 2016 Q2 | 311.12 Million HKD | 0.0% |
| 2016 FY | 435.61 Million HKD | -18.28% |
| 2015 Q4 | 533.07 Million HKD | 0.0% |
| 2015 Q2 | 348.4 Million HKD | 0.0% |
| 2015 FY | 533.07 Million HKD | 78.2% |
| 2014 Q3 | -250.95 Million HKD | -487.19% |
| 2014 FY | 299.14 Million HKD | 203.07% |
| 2014 Q1 | -400.9 Million HKD | -506.17% |
| 2014 Q4 | 299.14 Million HKD | 219.2% |
| 2014 Q2 | 64.81 Million HKD | 116.17% |
| 2013 Q1 | -241.93 Million HKD | -159.13% |
| 2013 Q4 | 98.7 Million HKD | 133.74% |
| 2013 FY | 98.7 Million HKD | 205.72% |
| 2013 Q3 | -292.51 Million HKD | -377.94% |
| 2013 Q2 | 105.24 Million HKD | 143.5% |
| 2012 Q1 | -145.42 Million HKD | -19939.56% |
| 2012 Q4 | -93.36 Million HKD | 73.78% |
| 2012 Q3 | -356.14 Million HKD | -2206.34% |
| 2012 FY | -93.36 Million HKD | -12837.52% |
| 2012 Q2 | -15.44 Million HKD | 89.38% |
| 2011 Q4 | 733 Thousand HKD | 0.0% |
| 2011 FY | 733 Thousand HKD | 102.46% |
| 2011 Q2 | 28.05 Million HKD | 0.0% |
| 2010 FY | -29.73 Million HKD | 0.23% |
| 2010 Q2 | -37.01 Million HKD | 0.0% |
| 2010 Q4 | -29.73 Million HKD | 0.0% |
| 2009 Q4 | -29.8 Million HKD | 0.0% |
| 2009 FY | -29.8 Million HKD | -195.24% |
| 2008 FY | 31.29 Million HKD | -76.29% |
| 2007 FY | 131.98 Million HKD | 174.42% |
| 2006 FY | -177.35 Million HKD | -830.83% |
| 2005 FY | 24.26 Million HKD | -79.12% |
| 2004 FY | 116.23 Million HKD | 168.19% |
| 2003 FY | 43.34 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 216.557% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 85.16% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -4972.948% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 1683.864% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -874.331% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 237.544% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | -17.712% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 20.133% |
| SSY Group Limited | 1.71 Billion HKD | 82.403% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 4175.362% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 10.641% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.409% |